Amended Current Report Filing (8-k/a)
March 04 2021 - 4:53PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
March 4, 2021
Onconova
Therapeutics, Inc.
(Exact name of Registrant as specified in
its charter)
Delaware
|
001-36020
|
22-3627252
|
(State or Other Jurisdiction
|
(Commission
|
(I.R.S. Employer
|
of Incorporation or Organization)
|
File Number)
|
Identification No.)
|
375 Pheasant Run
Newtown, PA 18940
(267) 759-3680
(Address, Including Zip Code, and Telephone
Number, Including Area Code, of Registrant’s Principal Executive Offices)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $.01 per share
|
|
ONTX
|
|
The Nasdaq Stock Market LLC
|
Common Stock Warrants
|
|
ONTXW
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
EXPLANATORY NOTE
This Form 8-K/A is filed as an amendment (“Amendment No.
1”) to the Current Report on Form 8-K filing by Onconova Therapeutics, Inc. (the “Company”) with the Securities
and Exchange Commission on March 4, 2021 (the “Original Report”). Amendment No. 1 is being filed to amend and supplement
the Company’s disclosures under Item 5.07 and Item 8.01 of the Original Report to include the final certified voting results
from the 2021 Special Meeting of Stockholders (the “Special Meeting”) held on March 4, 2021.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On March 4, 2021, the Company held the Special Meeting.
At the Special Meeting, the Company’s stockholders voted on the following proposal:
Proposal 3. To authorize one or
more adjournments of the meeting, if necessary, to solicit additional proxies if there are insufficient votes in favor of the Reverse
Stock Split (defined below) and/or Authorized Shares Decrease Proposal (defined below) at the Special Meeting or any adjournment(s)
thereof. The proposal was approved by a vote of the stockholders as follows:
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
|
81,214,871
|
|
24,142,103
|
|
4,653,122
|
|
None
|
|
Item 8.01 Other Events.
In accordance with Proposal 3, which was approved by
the stockholders, the Special Meeting was adjourned to April 1, 2021, at 9 a.m. Eastern Time with respect to Proposal 1 to consider
and vote upon an amendment to the Company’s Tenth Amended and Restated Certificate of Incorporation, as amended, to combine
outstanding shares of the Company’s common stock into a lesser number of outstanding shares, or a “Reverse Stock Split”,
by a ratio of not less than one-for-five and not more than one-for-fifteen, with the exact ratio to be set within this range by
the Company’s Board of Directors in its sole discretion (the “Reverse Stock Split Proposal”); and Proposal 2
to approve an amendment to the Company’s Tenth Amended and Restated Certificate of Incorporation, as amended, to decrease,
concurrent with and conditioned upon the effectiveness of the Reverse Stock Split, the number of authorized shares of capital stock
from 255,000,000 to 130,000,000 shares in order to decrease the number of authorized shares of common stock from 250,000,000 to
125,000,000 shares (the “Authorized Shares Decrease Proposal”). Approval of each of the Reverse Stock Split Proposal
and the Authorized Shares Decrease Proposal require the affirmative vote of the holders of a majority of the Company’s outstanding
shares of common stock.
The adjourned Special Meeting will be held at the same
virtual meeting location, www.virtualshareholdermeeting.com/ONTX2021SM. This will enable the Company’s stockholders of record
as of the record date, which was January 12, 2021, additional time to consider and vote on Proposal 1 and Proposal 2, and enable
the Company’s proxy solicitor, MacKenzie Partners, Inc., more time to assist the Company with the solicitation of stockholder
votes on Proposal 1 and Proposal 2.
At the adjourned Special Meeting on April 1, 2021, stockholders
will be deemed to be present in person and vote at such adjourned meeting in the same manner as disclosed in the definitive proxy
statement the Company filed with the Securities and Exchange Commission on January 13, 2021 and mailed to the stockholders. Valid
proxies submitted prior to the reconvened Special Meeting will continue to be valid for the upcoming reconvened Special Meeting,
unless properly changed or revoked prior to votes being taken at such reconvened Annual Meeting.
The Company's Board of Directors expects to communicate with
stockholders in the near future in connection with the adjourned Special Meeting.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 4, 2021
|
Onconova Therapeutics, Inc.
|
|
|
By:
|
/s/ MARK GUERIN
|
|
|
Name: Mark Guerin
|
|
|
Title: Chief Financial Officer
|
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Apr 2023 to Apr 2024